Targeting non-canonical pathways as a strategy to modulate the sodium iodide symporter.

Autor: Read ML; Institute of Metabolism and Systems Research (IMSR), and Centre of Endocrinology, Diabetes and Metabolism (CEDAM), University of Birmingham, Birmingham B15 2TT, UK., Brookes K; Institute of Metabolism and Systems Research (IMSR), and Centre of Endocrinology, Diabetes and Metabolism (CEDAM), University of Birmingham, Birmingham B15 2TT, UK., Thornton CEM; Institute of Metabolism and Systems Research (IMSR), and Centre of Endocrinology, Diabetes and Metabolism (CEDAM), University of Birmingham, Birmingham B15 2TT, UK., Fletcher A; Institute of Metabolism and Systems Research (IMSR), and Centre of Endocrinology, Diabetes and Metabolism (CEDAM), University of Birmingham, Birmingham B15 2TT, UK., Nieto HR; Institute of Metabolism and Systems Research (IMSR), and Centre of Endocrinology, Diabetes and Metabolism (CEDAM), University of Birmingham, Birmingham B15 2TT, UK., Alshahrani M; Institute of Metabolism and Systems Research (IMSR), and Centre of Endocrinology, Diabetes and Metabolism (CEDAM), University of Birmingham, Birmingham B15 2TT, UK., Khan R; Institute of Metabolism and Systems Research (IMSR), and Centre of Endocrinology, Diabetes and Metabolism (CEDAM), University of Birmingham, Birmingham B15 2TT, UK., Borges de Souza P; Section of Endocrinology, Department of Medical Sciences, University of Ferrara, Ferrara 44124, Italy., Zha L; Institute of Metabolism and Systems Research (IMSR), and Centre of Endocrinology, Diabetes and Metabolism (CEDAM), University of Birmingham, Birmingham B15 2TT, UK., Webster JRM; Protein Expression Facility, College of Medical and Dental Sciences, University of Birmingham, B15 2TT, UK., Alderwick LJ; Birmingham Drug Discovery Facility, School of Biosciences, University of Birmingham, Birmingham B15 2TT, UK., Campbell MJ; Division of Pharmaceutics and Pharmacology, The Ohio State University, College of Pharmacy, Columbus, OH 43210, USA., Boelaert K; Institute of Applied Health Research, University of Birmingham, Birmingham B15 2TT, UK., Smith VE; Institute of Metabolism and Systems Research (IMSR), and Centre of Endocrinology, Diabetes and Metabolism (CEDAM), University of Birmingham, Birmingham B15 2TT, UK., McCabe CJ; Institute of Metabolism and Systems Research (IMSR), and Centre of Endocrinology, Diabetes and Metabolism (CEDAM), University of Birmingham, Birmingham B15 2TT, UK. Electronic address: mccabcjz@bham.ac.uk.

Publikováno v: Cell chemical biology [Cell Chem Biol] 2022 Mar 17; Vol. 29 (3), pp. 502-516.e7. Date of Electronic Publication: 2021 Sep 13.

Sodium-iodide symporter and its related solute carriers in thyroid cancer.

Autor: Zhongqin Gong, Minghui Wei, Vlantis, Alexander C., Chan, Jason Y. K., Van Hasselt, C. Andrew, Dongcai Li, Xianhai Zeng, Lingbin Xue, Tong, Michael C. F., Chen, George G.

Publikováno v: Journal of Endocrinology; Apr2024, Vol. 261 Issue 1, p59-70, 12p

Progressive axonopathy when oligodendrocytes lack the myelin protein CMTM5.

Autor: Buscham, Tobias J., Eichel-Vogel, Maria A., Steyer, Anna M., Jahn, Olaf, Strenzke, Nicola, Dardawal, Rakshit, Memhave, Tor R., Siems, Sophie B., Müller, Christina, Meschkat, Martin, Ting Sun, Ruhwedel, Torben, Möbius, Wiebke, Krämer-Albers, Eva-Maria, Boretius, Susann, Nave, Klaus-Armin, Werner, Hauke B.

Publikováno v: eLife; 3/11/2022, p1-27, 27p

Information content differentiates enhancers from silencers in mouse photoreceptors.

Autor: Friedman, Ryan Z., Granas, David M., Myers, Connie A., Corbo, Joseph C., Cohen, Barak A., White, Michael A.

Publikováno v: eLife; 10/5/2021, p1-25, 25p

Abstract 5053: A critical role for copper in enhanced radioirdide uptake in thyroid cancer cells

Autor: Katie Brookes, Ling Zha, Jana Kim, Vinodh Kannappans, Weiguang Wang, Kavitha Sunassee, Philip J. Blower, Vicki E. Smith, Martin L. Read, Christopher J. McCabe

Publikováno v: Cancer Research. 83:5053-5053

New drug approaches are urgently required to improve radioiodide (RAI) uptake for efficient ablation of thyroid cancer cells in RAI-refractory disease. Employing high-throughput screening of FDA-approved compounds we recently identified drugs capable

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::57a82c33e546abe993e12c1f71ea0342
https://doi.org/10.1158/1538-7445.am2023-5053